The main treatment strategies for advanced PCa focus on the dependency of PCa cells on androgens and work by inhibition of the androgen receptor (AR) axis by blocking androgen production (i.e., degarelix, abiraterone) or direct targeting of the AR (i.e., bicalutamide, enzalutamide) (Crona and Whang, 2017). The gene discussed is AR; the disease is posterior cortical atrophy.